Prestige Consumer Healthcare Inc
F:PBV
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Prestige Consumer Healthcare Inc
NYSE:PBH
|
3.2B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
992.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
575.5B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
282.2B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
231.1B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.7B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.2B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Prestige Consumer Healthcare Inc
Glance View
Prestige Consumer Healthcare Inc. has carved out its niche in the competitive realm of over-the-counter healthcare products with a distinct flair. Born out of a series of insightful acquisitions and strategic brand cultivations, the company has crafted a portfolio that caters to a broad spectrum of consumer health needs. It offers an expansive range of products, from well-known pain relievers and eye care items to gastrointestinal treatments and women’s health solutions. The cornerstone of Prestige's success lies in its acute understanding of consumer demand and its agile response to market trends. By developing and acquiring brands that are established household names—such as Clear Eyes, Chloraseptic, and Dramamine—the firm has effectively secured a reliable revenue stream. Each brand, while under the corporate umbrella of Prestige, thrives on its ability to resonate with consumers who seek trustworthy, easily accessible remedies. Central to Prestige’s business model is its adeptness at maintaining and enhancing brand equity. Through a blend of focused marketing strategies and disciplined cost management, the company ensures consistent visibility and availability of its products across key retail channels, including mass merchandisers, drug retailers, and e-commerce. Prestige's skillful navigation of the marketplace allows it to capitalize on scale economies and maintain healthy margins. Each product in its portfolio is not only a testament to its commitment to quality and efficacy but also to its strategic foresight in addressing the ever-evolving healthcare challenges faced by consumers. In essence, Prestige Consumer Healthcare Inc. thrives by blending astute brand management with a keen focus on consumer health trends, ensuring its position as a formidable player in the healthcare industry.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Prestige Consumer Healthcare Inc is 56.1%, which is above its 3-year median of 55.4%.
Over the last 3 years, Prestige Consumer Healthcare Inc’s Gross Margin has decreased from 56.4% to 56.1%. During this period, it reached a low of 54.9% on Jun 30, 2023 and a high of 56.4% on Aug 30, 2022.